These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16300476)

  • 81. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract]   [Full Text] [Related]  

  • 82. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
    Giembycz MA
    Drugs; 2000 Feb; 59(2):193-212. PubMed ID: 10730545
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.
    Lagente V; Martin-Chouly C; Boichot E; Martins MA; Silva PM
    Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():131-6. PubMed ID: 15962112
    [TBL] [Abstract][Full Text] [Related]  

  • 84. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4.
    Sasaki K; Manabe H
    Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
    Giembycz MA; Smith SJ
    Curr Pharm Des; 2006; 12(25):3207-20. PubMed ID: 17020529
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Phosphodiesterases: the journey towards therapeutics.
    Torphy TJ; Page C
    Trends Pharmacol Sci; 2000 May; 21(5):157-9. PubMed ID: 10885973
    [No Abstract]   [Full Text] [Related]  

  • 87. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
    Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
    Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
    [TBL] [Abstract][Full Text] [Related]  

  • 88. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
    Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
    J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
    Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Multiplicity within cyclic nucleotide phosphodiesterases.
    Rybalkin SD; Beavo JA
    Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
    [No Abstract]   [Full Text] [Related]  

  • 91. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
    Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
    J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Increased building block access through collaboration.
    Helal CJ; Bartolozzi A; Goble SD; Mani NS; Guzman-Perez A; Ohri AK; Shi ZC; Subramanyam C
    Drug Discov Today; 2018 Aug; 23(8):1458-1462. PubMed ID: 29571837
    [No Abstract]   [Full Text] [Related]  

  • 94. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.
    Xu RX; Hassell AM; Vanderwall D; Lambert MH; Holmes WD; Luther MA; Rocque WJ; Milburn MV; Zhao Y; Ke H; Nolte RT
    Science; 2000 Jun; 288(5472):1822-5. PubMed ID: 10846163
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 96. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.
    Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phosphodiesterase 4D and heart failure: a cautionary tale.
    Lehnart SE; Marks AR
    Expert Opin Ther Targets; 2006 Oct; 10(5):677-88. PubMed ID: 16981825
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.
    Wen RT; Zhang FF; Zhang HT
    Psychopharmacology (Berl); 2018 Jun; 235(6):1793-1805. PubMed ID: 29663017
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.
    Ochiana SO; Bland ND; Settimo L; Campbell RK; Pollastri MP
    Chem Biol Drug Des; 2015 May; 85(5):549-64. PubMed ID: 25283372
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
    Amata E; Bland ND; Hoyt CT; Settimo L; Campbell RK; Pollastri MP
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4084-9. PubMed ID: 25127163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.